Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb has received the US Food and Drug Administration (FDA) approval for Nulojix (belatacept) as a preventive measure for acute rejection in adult patients following kidney transplantation.
Subscribe to our email newsletter
The drug demonstrated safety profile and positive results when investigated in open-label, randomized, multicenter, controlled Phase 3 studies comparing two dose regimens of Nulojix with another immunosuppressant cyclosporine.
The drug was safe and effective in prevention of acute organ rejection.
FDA Center for Drug Evaluation and Research Office of Antimicrobial Products director Edward Cox said Nulojix is a new option for kidney transplant patients.
"This new medication used in combination with other immunosuppressants helps control the immune system and prevents organ rejection in patients receiving kidney transplants," Cox said.